Planmeca Ultra Low Dose™ technology scientifically proven in several studies

Planmeca has earned a reputation as the leader in low dose CBCT imaging. The Planmeca Ultra Low Dose™ protocol has been studied in several studies, one of which concluded that the technology reduces patient doses by up to 77% with no statistical reduction in image quality between the standard and ultra low dose protocols. A recently published sixth clinical study on Planmeca Ultra Low Dose confirmed the effectiveness and quality of the technology once again.

Planmeca Ultra Low Dose™ technology scientifically proven in several studies

News Apr 13, 2022

The Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology journal recently published a study that concluded that the overall image quality was at a diagnostically acceptable level for the defined diagnostic task using the Planmeca Ultra Low Dose™ (ULD) protocol. Additionally, the study remarked that applying Planmeca AINO™ noise reduction filter had a positive effect on image quality when the exposure dose was low, a typical by-product when reducing radiation.

Similarly, other studies previously concluded e.g. that:
- Planmeca Ultra Low Dose is recommended for pre-implant radiographic assessment
- Cephalometric images reconstructed from Planmeca Ultra Low Dose CBCT images should be considered in orthodontic treatment planning
- Planmeca Ultra Low Dose images have sufficient diagnostic image quality to be used in a paediatric setting for planning and follow-up imaging

Planmeca's success in lowering patient dose is important not only because it reduces risk to the patient, but also because it allows clinicians to employ CBCT technology in a wider variety of applications. And, while research is conducted to study and validate the effects of technological advancements, the real winners of this scientifically proven technology are the patients. Dental professionals that employ Planmeca Ultra Low Dose imaging are acquiring CBCT scans that are diagnostically acceptable for the task while significantly reducing patient exposure. Many Planmeca customers have discovered that radiation levels using ULD are often less than that of traditional 2D radiology while the ULD images provide plenty of data to support efficient and accurate diagnoses and predictable treatment outcomes –another patient benefit.

Dr Peter Green, a Board Certified Dental Radiologist, has experience reviewing CBCT scans at all resolutions and voxel sizes. According to Dr Green, image quality is extremely important when it comes to diagnostic value and making a proper evaluation. "I see the best and the worst DICOM files come across my desk. Planmeca CBCT systems consistently produce high quality images, and as a radiologist, it is reassuring when I see scans utilising Planmeca Ultra Low Dose. Not only do I have a diagnostically viable image, I also know the patient has not been exposed to unnecessarily high doses of radiation."

Dr Green also prefers reviewing 3D images over 2D. "Two-dimensional studies have been the cornerstone of dental imaging since its inception. But, the diagnostic value of 2D is limited. When we review a 2D image, we uncover distortion of anatomy because of angulation and magnification errors. We also see overlapping anatomy which is inevitable with 2D imaging. These kind of inherent inaccuracies often hide small apical lesions, such as those confined between the cortical plates. With 2D, you are in fact only seeing part of the picture. CBCT allows viewing from any perspective and with no distortion. With Planmeca Ultra Low Dose technology, providers no longer have to sacrifice excellent image quality to achieve a significant reduction in dose. This makes it possible to enjoy the benefit of 3D information for the dose of a panoramic or even a set of bitewings," he explains.

"When it comes to innovation, Planmeca is the industry leader," says Brent Garvin, Senior Product Manager for Imaging in North America at Planmeca USA, a subsidiary of Planmeca in the United States. Garvin expresses tremendous pride when representing products developed by Planmeca's R&D team in Finland. "We continue to strive to help doctors be better at their job while focusing on patient safety. This is our sixth major study validating the effects of ULD on our industry," Brent continues. "This is exciting because no one else in the industry has this kind of validation from so many sources."

Another exclusive feature aimed at increasing patient safety is the Planmeca CALM® movement correction algorithm. "We have drastically reduced the risk of having to redo a 3D scan because the patient shifted their weight during acquisition or swallowed. This feature recognises patient movement and automatically makes the correction resulting in a diagnostically valuable image," Garvin explains. "It doesn't get any easier than this."

"Planmeca is currently the only manufacturer in the market with these advanced features and the evidentiary clinical studies to support the claims. The implications of ultra low dose patient radiation paired with diagnostically valuable image quality is paving the way for CBCT use in routine diagnostics validating the Planmeca slogan – Better care through innovation," Garvin concludes.

To learn more about Planmeca Ultra Low Dose and access these studies, visit

About Planmeca USA:
Planmeca USA is a subsidiary of Planmeca, the largest privately held company in the dental equipment market and one of the industry’s leading manufacturers of dental X-rays and core equipment. With a North American office located in Hoffman Estates, Illinois, and international headquarters in Helsinki, Finland, Planmeca is well established in high-tech dental markets and currently serves 120 countries worldwide.

Planmeca Oy and Planmeca Group
Planmeca Oy is one of the world's leading dental equipment manufacturers, with a product range covering digital dental units, CAD/CAM solutions, world-class 2D and 3D imaging devices and comprehensive software solutions. Privately owned and headquartered in Helsinki, Finland, the company offers a portfolio of products distributed in over 120 countries worldwide. Planmeca Oy is part of the Finnish Planmeca Group, which consists of several healthcare technology brands, each committed to innovation and design. With 4,500 employees worldwide, Planmeca Group companies achieved a combined turnover of EUR 1.1 billion in 2020.

For more information, please contact:

Emilia Jyrkiäinen
Product Manager, X-ray
+358 20779 6036

North American markets:

Lou Vodopivec
Vice President of Marketing and Education
+1 630 529 2300

Related News